Cannabis Users Show Better Cognition, No Dementia Risk: New Research
New study finds lifetime cannabis use linked to superior cognitive performance in older adults, potentially reshaping medical cannabis market dynamics.
New research challenges long-standing assumptions about cannabis and brain health, revealing that lifetime cannabis users demonstrate superior cognitive performance compared to non-users. The study found no association between cannabis consumption and increased dementia risk, while also failing to establish any causal relationship between cannabis use and cognitive decline in aging populations.
The findings arrive at a pivotal moment for the medical cannabis sector, where companies like Tilray Brands (TLRY) and Canopy Growth (CGC) continue expanding their pharmaceutical divisions. This research could accelerate institutional acceptance of cannabis-based therapeutics, particularly as the global medical cannabis market approaches $50 billion by 2028. The cognitive health angle represents an untapped revenue stream that could drive significant valuation increases across the sector.
These results directly contradict decades of anti-cannabis messaging and provide scientific backing for the growing senior demographic embracing cannabis products. Companies targeting older consumers, including multi-state operators like Curaleaf (CURA) and Cresco Labs (CL), stand to benefit from reduced stigma and increased medical legitimacy. The 65-plus age group represents the fastest-growing cannabis consumer segment, with spending increasing 25% annually.
The research strengthens arguments for federal rescheduling and expanded clinical trials, potentially accelerating FDA approval pathways for cannabis-derived medications. This regulatory momentum could trigger institutional investment flows into cannabis stocks, which remain largely excluded from major indices due to federal prohibition. Companies with robust R&D pipelines and pharmaceutical partnerships position themselves to capitalize on evolving medical applications.
Investors should monitor how this research influences upcoming congressional hearings on cannabis policy and FDA guidance on medical applications. The cognitive health findings provide compelling evidence for lawmakers considering comprehensive reform, while offering cannabis companies new marketing angles for products targeting age-related health concerns. This scientific validation could mark an inflection point where cannabis transitions from recreational novelty to legitimate pharmaceutical category.